Format

Send to

Choose Destination
Am J Surg. 2014 Aug;208(2):210-4. doi: 10.1016/j.amjsurg.2013.10.030. Epub 2014 Jan 24.

The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients.

Author information

1
Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria; Research Unit: Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria.
2
Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria.
3
Division of General Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
4
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
5
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
6
Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria; Research Unit: Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria. Electronic address: armin.gerger@medunigraz.at.

Abstract

BACKGROUND:

Recent evidence indicates that tumor progression involves factors of systemic inflammation, such as platelets and lymphocytes. In this study, we investigated the prognostic relevance of the preoperative platelet to lymphocyte (P/L) ratio on time to recurrence (TTR) and overall survival (OS) in patients with stage II and III colon cancer (CC) who underwent curative resection.

METHODS:

In this retrospective study, 372 CC patients were included. Kaplan-Meier curves and multivariate Cox proportional models were calculated for TTR and OS.

RESULTS:

In univariate analysis, the elevated P/L ratio was significantly associated with decreased TTR (HR = 1.60, 95% CI = 1.02 to 2.51, P = .040) and remained significant in multivariate analysis (HR = 1.65, 95% CI = 1.05 to 2.58, P = .030), where HR and CI represent Hazard ratio and confidence interval, respectively. Patients with elevated P/L ratio showed a median TTR of 116 months. In contrast, patients with low P/L ratio had a median TTR of 132 months. In OS analysis, the elevated P/L ratio showed a trend toward decreased OS in univariate analysis (HR = 1.54, 95% CI = .95 to 2.48, P = .079).

CONCLUSION:

In this study, we identified the preoperative P/L ratio as a prognostic marker for TTR in stage II and III CC patients.

KEYWORDS:

Colon cancer; Platelet to lymphocyte ratio; Prognostic factor; Systemic inflammation

PMID:
24581872
DOI:
10.1016/j.amjsurg.2013.10.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center